Treatment-related myelodysplastic syndrome/acute myeloid leukemia in survivors of childhood cancer--an update.
Treatment-related myelodysplastic syndrome/acute myeloid leukemia (t-MDS/t-AML) is a devastating complication of treatment for childhood cancer. However, the major cause of premature death of children treated for cancer remains their primary cancer. The understanding of the presentation, incidence, predisposing risk factors and pathobiology of t-MDS/t-AML is increasing. This increased understanding has not yet been translated into improved outcomes of therapy for t-MDS/t-AML. However, newer approaches are under study.
Barnard
D R
DR
Division of Pediatric Hematology/Oncology, IWK Health Center, 5850 University Ave, Halifax, Nova Scotia, Canada. dorothy.bernard@iwk.nshealth.ca
Woods
W G
WG
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D002648:Child; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000139:chemically induced / Q000209:etiology*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000139:chemically induced / Q000209:etiology*; D009369:Neoplasms / Q000628:therapy; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000209:etiology* / Q000235:genetics; D017741:Survivors
D000970:Antineoplastic Agents